Cargando…
Assessment of Retinal Pigment Epithelium Alterations and Chorioretinal Vascular Network Analyses in Patients under Treatment with BRAF/MEK Inhibitor for Different Malignancies: A Pilot Study
In the last two decades, an increasing number of so-called molecular-targeted therapies have become available for the treatment of patients with advanced malignancies. These drugs have included inhibitors of proteins in the MAPK pathway, such as BRAF and MEK inhibitors, which are characterized by a...
Autores principales: | Fasolino, Giuseppe, Awada, Gil, Moschetta, Laura, Koulalis, Jorgos Socrates, Neyns, Bart, Verhelst, Bert, Van Elderen, Peter, Nelis, Pieter, de Lichtbuer, Paul Cardon, Cools, Wilfried, Ten Tusscher, Marcellinus |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
MDPI
2023
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9918243/ https://www.ncbi.nlm.nih.gov/pubmed/36769861 http://dx.doi.org/10.3390/jcm12031214 |
Ejemplares similares
-
Acute exudative polymorphous vitelliform maculopathy during pembrolizumab treatment for metastatic melanoma: a case report
por: Lambert, Ine, et al.
Publicado: (2021) -
Choroidal and Choriocapillaris Morphology in Pan-FGFR Inhibitor-Associated Retinopathy: A Case Report
por: Fasolino, Giuseppe, et al.
Publicado: (2022) -
A Phase 2 Clinical Trial of Trametinib and Low-Dose Dabrafenib in Patients with Advanced Pretreated NRAS(Q61R/K/L) Mutant Melanoma (TraMel-WT)
por: Awada, Gil, et al.
Publicado: (2021) -
Inhibition of BRAF and BRAF+MEK drives a metastatic switch in melanoma
por: Smalley, Keiran SM, et al.
Publicado: (2015) -
Medical debulking with BRAF/MEK inhibitors in aggressive BRAF-mutant craniopharyngioma
por: Di Stefano, Anna Luisa, et al.
Publicado: (2020)